Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.
| Autor: | Shah MA; New York Hospital/Weill Cornell Medical Center, New York, NY., Kennedy EB; American Society of Clinical Oncology, Alexandria, VA., Catenacci DV; University of Chicago Medicine, Chicago, IL., Deighton DC; Alexandria, VA., Goodman KA; Icahn School of Medicine at Mount Sinai, New York, NY., Malhotra NK; Yolanda G. Barco Cancer Institute, Meadville, PA., Willett C; Duke Cancer Center, Durham, NC., Stiles B; New York Hospital/Weill Cornell Medical Center, New York, NY., Sharma P; University of Kansas School of Medicine and VAMC, Kansas City, KS., Tang L; Memorial Sloan Kettering Cancer Center, New York, NY., Wijnhoven BPL; Erasmus University Medical Center, Rotterdam, the Netherlands., Hofstetter WL; The University of Texas MD Anderson Cancer Center, Houston, TX. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Aug 10; Vol. 38 (23), pp. 2677-2694. Date of Electronic Publication: 2020 Jun 22. |
| DOI: | 10.1200/JCO.20.00866 |
| Abstrakt: | Purpose: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. Methods: ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. Results: Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. Recommendations: Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|